DEA Orders Big Pharma Opioid Distributor to Shut Down Sales

DEA Orders Big Pharma Opioid Distributor to Shut Down Sales

For the first time in six years, the DEA has ordered a suspension on a pharmaceutical wholesaler, and it’s a Big Pharma opioid distributor- Morris & Dickson.

We now know that officials all over the country, both at the state and federal levels, are joining forces to go after Big Pharma companies for pushing powerful opioid painkillers that contributed to one of the greatest addiction outbreaks in American history. While not everyone agrees on the role prescription drugs played in the opioid crisis, many believe the questionable marketing and distribution practices is reason enough for real intervention.

Lawsuits against opioid makers are taking place all over the US, and distribution companies are finding themselves in the hot seat.

DEA vs Opioid Distributor

This latest news comes following an investigation into Morris & Dickson. Allegedly, the investigation uncovered evidence that the Big Pharma opioid distributor neglected to inform the DEA about large quantities of addiction painkillers being bought up by independent pharmacies.

This is a problem because, according to The Hill, reporting such information to the DEA is a requirement.

Back in October of 2017 the investigation into the opioid distributor out of Shreveport, Louisiana got kicked off after reports came in that Morris & Dickson had sold narcotics to five of the state’s top 10 drug-purchasing pharmacies, but never filed any suspicious activity reports in any of these cases. In a statement Friday, the Justice Department revealed that according to the DEA investigation, independent pharmacies were allowed to purchase six times the amount they would normally order from the opioid distributor.

For the record- pharmaceutical distributors like Morris & Dickson are legally required to report unusually large shipments of narcotics to the government as a safeguard against prescription medications from making their way to the illicit drug market. DEA Acting Administrator Robert W. Patterson said in a statement:

“Distributors have an obligation to ensure that all pharmaceutical controlled substances their customer’s order are for legitimate use, and it is their duty to identify, recognize and report suspicious orders to DEA,”

“This is another reminder that DEA will hold accountable those companies who choose to operate outside the law.”

The Big Pharma opioid distributor will have the chance to appeal the suspension during an administrative hearing.

Morrison & Dickson Fight Back

Let the record show that Morrison & Dickson are definitely not taking these charges sitting down. The opioid distributor has struck back against the suspension with a federal lawsuit. They adamantly hold that they will fight the suspension. Company president Paul M. Dickson released his own statement, saying:

“Sadly, in this case, the DEA has gotten it wrong. We would’ve proved that to them had they given us the chance.”

They already asked a judge last Thursday to overturn the DEA suspension. In the legal claim against the DEA order the opioid distributor states:

“Make no mistake—this is a life and death situation. Morris & Dickson services 30-40% of the hospital drug market in Louisiana and Texas alone. If Morris & Dickson cannot ship needed medications to these hospitals, these hospitals may face immediate drug shortages.”

The company president also maintains that the opioid distributor has already greatly reduced its circulation of opioids. Dickson emphasizes that the company provides medications that many patients do desparately need. He also acknowledges the devastation caused by the opioid crisis, saying:

“Everyone in the Morris & Dickson family has been touched by the opioid crisis. That’s why we’ve taken aggressive and effective voluntary measures against any potential opioid diversion from medical use. We have reduced our opioid distribution dramatically. And it’s why we’re so proud of our history of 177 years with no outside enforcement actions against us.”

At this point, only time will tell if the company will have to adhere to the suspension for much longer.

Some people argue that moves like this from the DEA are too aggressive or an over-reach. However, given the circumstances, this seems like a logical response. Looking at the massive shipments of Oxycodone and Hydrocodone, it seems like it shouldn’t be too much to ask they notify the DEA.

What is Next?

Big Pharma executives testified for Congress yesterday, answering questions about their role in the prescription drug problem. The Washington Post reports that this could be a defining moment for the opioid industry. Witnesses for the hearing included high ranking executives from:

  • Miami-Luken, INC
  • McKesson Corporation
  • Cardinal Health
  • AmerisourceBergen Corporation
  • HD Smith Wholesale Drug Company

During the hearing, Congressman Gregg Harper of Mississippi states:

“We have learned much from the investigation but still have many questions,”

“Why did the distributors repeatedly fail to report suspicious orders of opioids or exercise effective controls against diversion?”

He goes on to explain that the DEA identified opioid distributor companies as a key element to combating the diversion of drugs to the black market. He states that distributors have often claimed that they were too limited to properly address these issues, as they do not understand the whole scope as the DEA does. However, he argues that distributors do have a great deal of data collection, and should be aware of their impact.

According to Congressman Harper, distributors also frequently argue that they are simply providing a service. They do not control the demand, but simply offer the supply based on the prescriptions from physicians. This argument seems a bit of a cop-out, and almost sounds like something a street-level drug dealer would say.

The committee also adds that over the course of 6 years, opioid distributor companies filled the state of West Virginia with over 780 million Hydrocodone and Oxycodone pills, while 1,728 people in West Virginia fatally overdosed on those two painkillers.

In their opening statements, each Big Pharma distributor representative acknowledged the devastation of the epidemic. However, when asked by Chairman Harper if they believed their companies contributed to the opioid epidemic, except for the chairman of the board for Miami-Luken Dr. Robert E. Mastandrea, they all said no.

In fact, Dr. Mastandrea seemed to be the only one consistently willing to admit that Miami-Luken had made mistakes that helped create the opioid crisis.

While it will take time to determine the impact of these testimonies, one thing we can say now is that drug distribution companies are quickly finding themselves on the chopping block when it comes down to the efforts to curb prescription opioids abuse.

For now, a crucial part of fighting the opioid epidemic is going to be providing safe and effective addiction treatment. It may not be easy to put a stop to the spread of addiction, but there are programs that can help you break out of the cycle of drug and alcohol abuse. If you or someone you love is struggling, please call toll-free now. We want to help.

Sober Slim Shady: 10 Years of Eminem in Recovery

Sober Slim Shady: 10 Years of Eminem in Recovery

Eminem; Marshall Bruce Mathers III; The Real Slim Shady, is not just an icon in rap who had an unfathomable impact on hip-hop culture. He is also a man who has endured a lifetime of public controversy, private conflict, personal loss and emotional pain. Not only does this make his music career that much more powerful, but it makes his journey through addiction and recovery that much more gripping. With Eminem celebrating 10 years of sobriety this month, we take a quick look at the story of sober Slim Shady.

Eminem Celebrating Sobriety

A few days ago, between his headlining sets at this year’s Coachella, 45-year-old Marshall Mathers took to social media to share a message with his fans. On Instagram Slim Shady posted a photo of his ten-year medallion on Saturday, April 21. The circle, marked with an ‘X’ for the Roman numeral ten, is a token he received to commemorate a decade of continuous sobriety. To caption the image, he wrote:

“Celebrated my 10 years yesterday”

In just 2 days’ time, the image had already garnered over 1.7 million likes and over 33,000 comments. He wasn’t the only one utilizing his social status to share that powerful moment. Fellow rap artist and friend in sobriety Royce Da 5’9” also took to Twitter to give the real Slim Shady a shout out for his recovery milestone, writing:

“Happy sobriety birthday to my mentor @Eminem… Keep fighting the good fight homie… I love you for life”

Eminem has also shared moments of his journey through recovery with other famous sober peers, including Sir Elton John. The post prompted many fans on social media to congratulate Mathers on his anniversary. Others shared how he had helped inspire many others in recovery.

The last ten years have not been easy for Slim Shady, but it seems they have been worth it.

A Quick Look at a Legend

Long before Eminem got sober, he was a household name and best selling artist. Over his whole career, he has had a truly incredible list of accomplishments, including:

  • 10 number-one albums on the Billboard 200
  • Five number-one singles on the Billboard Hot 100
  • 4 million albums sold in the US
  • 220 million records globally
  • He is among the world’s best-selling artists of all time
  • He is the only artist to have eight albums consecutively debut at number one on the Billboard 200
  • Winner of 15 Grammy Awards, including Best Rap Album

All of this, not to mention successful clothing lines, the creation of his label Shady Records which helped launch artists like 50 Cent and Yelawolf, and his own Sirius XM Radio channel, Shade 45. He gave us such gifts as D12 and Slaughterhouse, while also inspiring countless other artists.

Eminem isn’t only known for his music, but also for the controversy surrounding him. Whether it was the ugly battles with his mother, ex-wife, or the legal trouble he was conflicted with publically, it all fueled an image of a man who lived in a courtroom fighting painful scandals. He used the pain in his creative process, and the world was given a lot of angry, violent, and even poetic moments.

The Academy Award-winning film 8 Mile, which he starred in, made him the first rap artist to ever win the award for Best Original Song with “Lose Yourself”. Followed by various other film and entertainment ventures.

Oh, and don’t forget the Marshall Mathers Foundation, which aids disadvantaged youth.

The list just goes on and on. There is not enough time here to cover the truly immeasurable impact Eminem has had on not just hip-hop culture, but on the overall culture in America.

Getting to 10 Years

Slim Shady has always been pretty public about his struggles with addiction to prescription drugs. It is laced in his image over the years and is a prominent subject of his music. Back in 2002, a fellow artist said he had been trying to straighten out, but while working on 8 Mile he was introduced to Ambien and this prescription took him deeper down the path. When talking about working on his album Encore, Slim Shady once said he would “just go into the studio and goof off [with] a pocketful of pills”.

In 2007, Eminem suffered from an accidental methadone overdose after his addiction had spiraled out of control. At one point he revealed that he was taking up to 60 Valium and 30 Vicodin pills a day. After adding Ambien to the mix, he made his way to methadone by the end of his substance abuse. In 2011 when interviewed about the overdose, he stated:

“The doctors told me I’d done the equivalent of four bags of heroin… They said I was about two hours from dying.”

In a 2011 New York Times interview Slim Shady said,

“I used to get pills wherever I could. I was just taking anything that anybody was giving to me.”

Following that near-death experience, the Detroit rap legend chose to attend an addiction treatment program in Michigan. However, he ended up relapsing short of a month out of the hospital.

He reported that his star status made rehab difficult for him to focus on himself. Instead, he chose to detox at a hospital and dove into counseling and therapy. He credits his children, including his biological daughter Hailie, and two adopted daughters Lainey and Whitney. He also gives credit to exercise, saying that running helped him find a healthier high that helped him sleep.

When looking at his story, it is absolutely remarkable the impact that Slim Shady had had on the world of hip-hop or just music in general. He has been described by many as one of the greatest artists of all time, with billions of fans all over the globe. To hear about the life he lived; through poverty, depression, desperation, and addiction, to be a living legend only speaks to the inspiration in his experience, strength and hope. We celebrate the path Eminem walks and the work he has done over the years to make it this far.

Thank you for sharing, Slim Shady.

It can be a real inspiration to see some of the most successful people are recovering alcoholics and addicts. It reminds us that we all can suffer the same way and that we all have the same chance to build a better future. The more heroes we have every day that step up and share their message of hope, the more hope we may have that people seek the help they desperately need. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now.

CALL NOW 1-888-922-5398

The Trump Opioid Plan: the Good, the Bad and the Border

The Trump Opioid Plan: The Good, the Bad and the Border

The fight against prescription opioid abuse, heroin, and fentanyl in America continues to intensify. Our political landscape may soon see even more drastic shifts because of it. Controversy and conjecture have surrounded many ideas brought to the table on both sides. Even the President himself has been behind some pretty divisive propositions. Then Monday, President Trump unveiled his plan for combatting the ongoing opioid crisis in America while in New Hampshire.

During his speech, the President talked up a few key elements of his plan; some we have heard of before, and others have only recently become a serious topic of conversation. As the administration puts the final touches on their proposals, we thought should take a look at some of the highlights and see which of his plans could actually work, and why experts and advocates believe others probably won’t.

Arguably, there are some pretty good ideas here… and some pretty bad ones, depending on who you ask.

An Opioid Vaccine

Let’s kick this off on a high note.

The Trump opioid plan includes supporting the search for a vaccine. This honestly seems like a good ambition to get behind, but will it work? Researchers at the Walter Reed Army Institute of Research and the National Institute on Drug Abuse developed an experimental heroin vaccine back in December. So far the compound has been tested with rats and mice. Their latest breakthrough found that antibodies in the vaccine bound to the heroin before crossing the blood-brain barrier. This reaction effectively prevents the euphoric effects of the drug.

While this is an exciting development, it is still a vast leap to go from treating mice to treating humans. We still have a long road ahead before this possible vaccine could be approved. However, more funding and resources from the federal government could make a big difference.

Even so, it is important to note that this vaccine will not be a cure-all answer that fixes everything. After all, we have seen opioid blocking methods before. Drugs like Vivitrol and other implants were also developed to hamper the effects of opioids, and they still haven’t stopped the crisis from growing. Experts are already saying this vaccine will only work in the short term and require repeated doses. It is expected to be an incredibly expensive treatment, and it may only be another variation of the Vivitrol shot. Still, some believe this vaccine, used alongside other treatment methods, could be a crucial tool in fighting opioids.

Big Pharma and Prescription Drugs

The Trump opioid plan also takes a look at prescription opioids. The President acknowledged the contribution of pharmaceutical companies and prescription drugs to the opioid crisis. In his statement, he indicated that this administration support research for opioid alternatives.

“That includes federal funding for the development of non-addictive painkillers.”

In talking about prescription drugs, President Trump said the administration also planned on addressing the issue of overprescribing addictive medications. He even touted the Justice Department’s new task force that may soon be fighting Big Pharma companies in court.

“Our Department of Justice is looking very seriously into bringing major litigation against some of these drug companies. We will bring it at a federal level.”

He acknowledges the recent work at the state level to hold Big Pharma accountable. President Trump said his administration will be working to reduce opioid prescriptions by 1/3 over the next three years. Hopefully, as time goes on there will not only be more accountability to those manufacturing these potent medications, but also more options for the thousands of people suffering from chronic pain who do need pain management.

Commercial Campaign

This show we have seen (fail) before. The crisis probably isn’t going to get fixed with re-runs and reboots.

For a long time, Trump has been talking about creating a media campaign to try and combat the opioid crisis. In his remarks on Monday, the president said,

 “We are thinking about doing a really large-scale rollout of commercials that show how bad it is for the kids… Scare them from ending up like the people in the commercials.”

Trump said he would spend a lot of money and direct people to make the commercials depict “pretty unsavory situations” claiming that this strategy has worked before with cigarette smoking.

Sadly, the reality is that we have tried this before. Using anti-drug messaging that specifically targets kids and young adults is exactly what was done with the “Just Say No” ad campaign of the 1980s and early 1990s, and the DARE program of the same period. Neither program was proven to be particularly effective in reducing drug use. Some have even argued it did the opposite and actually intrigued young people into drug use.

This is just one part of the Trump opioid plan that reminds people of the ideas pushed in the failed War on Drugs that already destroyed countless lives and only ended up making the problem worse.

So how will this new campaign be different?

The Border

The President also mentioned the importance of combatting the flow of illicit drugs like fentanyl and heroin into the country. He became particularly energized of course when talking about his proposed border wall with Mexico, saying,

“90% of the heroin in America comes from the southern border, where eventually the Democrats will agree with us and we will build a wall to keep the damn drugs out.”

However, many are not so convinced that the wall will be especially effective in stopping drug traffickers. Support for the wall experiences ups and downs as negotiations over immigration continue. Then the President took the opportunity to scrutinize sanctuary cities, calling out California and claiming these places were harboring the most terrible kinds of criminals, including drug dealers.

If part of the Trump opioid plan is to apply even more pressure to sanctuary cities, we may see more back-and-forth when it comes to compromises on immigration policy reform. Recently the Republicans were using DACA as a bargaining chip with Democrats to get the infamous border wall built, but now Trump says Democrats are holding onto it so they can use the issue during the election cycle.

Death Penalty for Drug Dealers

Now, THIS proposal is the one part of the Trump opioid plan that is causing the most controversy, and understandably so.

UPDATE: Attorney General Jeff Sessions sent out a memo Wednesday officially asking federal prosecutors to pursue the death penalty in drug trafficking cases “dealing in extremely large quantities of drugs”. So the administration is now implementing President Donald Trump’s plan to ramp up “tough on crime” punishments in response to the opioid crisis.

In his speech, the President brought having the death penalty for drug traffickers to the forefront. This is an extreme even some of his supporters believed was more tongue-in-cheek than actual proposed policy. The details on this proposal were still pretty scarce at the time. Some support Trump pushing for the death penalty, saying this punishment would only apply to high volume, kingpin-level dealers. But what we should consider is this:

  1. The federal death penalty is available for a few drug offenses. This includes violations of the “drug kingpin” provisions in federal law.
  2. Reports indicate that Trump wants Congress to pass legislation that will reduce the amount of drugs needed to trigger mandatory minimum sentences for traffickers.

So should we assume that the President intends to expand what qualifies as “drug kingpin” activity to make the death penalty easier to enforce? If so, what does that mean exactly? And what does it mean for further enforcing other mandatory minimums?

The Justice Department has said it would seek the death penalty “when appropriate under current law.” While drug-related murder is already a capital offense, no one has ever been executed by those rules. However, President Trump says that he and the Justice Department are working very hard to change the laws. To do so would require an act of Congress, and many believe Congress is highly unlikely to expand the federal death penalty. So will any of this be changing soon?

In his comments, President Trump stated,

“If we don’t get tough on the drug dealers, we are wasting our time. And that toughness includes the death penalty.”

President Trump’s call for the death penalty is being strongly met with condemnation. The proposal’s critics range from treatment advocates to law enforcement officials and civil liberty organizations.

Maria McFarland Sánchez-Moreno, executive director of Drug Policy Alliance, said in a statement,

 “If this administration wants to save lives, it needs to drop its obsession with killing and locking people up, and instead focus resources on what works: harm reduction strategies and access to evidence-based treatment and prevention.”

Jesselyn McCurdy, deputy director of the American Civil Liberties Union’s Washington office, said,

“Drug trafficking is not an offense for which someone can receive the death penalty,”

McCurdy is referring to a Supreme Court precedent that puts constraints on using the death penalty for a convicted person who did not commit murder.

Furthermore, there are plenty of arguments that this kind of policy is not practical. Some say it would either be so broad it became unconstitutional, or so specific that it would be obsolete. This aspect of the plan has sparked nationwide debate. Americans everywhere are arguing whether or not a drug dealer should be responsible for the deaths of customers.

Sadly, this is so frustrating because past data does not hold with the idea that getting ‘tough’ on drugs is more effective than offering treatment opportunities. One of the best studies backing this is a 2014 study from Peter Reuter at the University of Maryland and Harold Pollack at the University of Chicago. Researchers determined that while simply prohibiting drugs to some extent does raise their prices, there’s no good evidence that tougher punishments or harsher supply elimination efforts do a better job of driving down access to drugs and substance misuse than lighter penalties.

In fact, many addiction advocates argue that harsher punishments can actually be counter-productive because they end up punishing people who need treatment, not incarceration. So the need for a more comprehensive approach to opioid addiction treatment is paramount. Hopefully, this administration will see the need to focus on support for treatment, instead of a primarily punitive focus.

Trump Opioid Plan on Treatment

This is a critical and commendable element of the Trump opioid plan, and I applaud some of its intentions. However, I wish we could talk a lot more about this and a lot less about captial punishment.

Still, I give them credit for saying they want to increase access to addiction treatment and adopting harm reduction. There isn’t much detail to go on though, as far as how this will happen. One aspect is to increase the use of medications such as methadone and buprenorphine.

As another highlight, Trump also asks Congress to repeal a rule blocking Medicaid payments to larger treatment facilities, which could provide a boost in the billions to inpatient clinics. Hopefully, this is one factor of the Trump opioid plan that will pan out, because one of the biggest issues the US faces with the opioid crisis is a limited access to adequate treatment options. If the White House allows Medicaid to reimburse larger treatment facilities, more people will be able to get effective care. Still, it is unclear how many resources the administration is willing to commit to treatment resources.

Hopefully, the Trump opioid plan will evolve and we will see a resurgence of resources going toward helping get people suffer the help they need. It is understandable to want to curb the rise of addiction through anti-trafficking measures and raising awareness, but we already have thousands and thousands of people struggling every day all over America who need help. Preventive steps are crucial, and the President is trying to push for them. But it is vital that we also give everyone already struggling more of a fighting chance. The possibility of more people having greater access could help create a huge shift.

Palm Healthcare Company believes in providing innovative and effective holistic treatment options for those who are battling with addiction. Our facilities believe in comprehensive and compassionate care, and our mission every day is to transform as many lives as possible. Together, we can make a difference. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now. We want to help.

CALL NOW 1-888-922-5398

Opioid Makers Will Soon Face New Justice Department Task Force

Opioid Makers Will Soon Face New Justice Department Task Force

Attorney General Jeff Sessions made an announcement at a news conference Tuesday that the Justice Department will be creating a new task force to pursue the makers and distributors of prescription opioids. It seems that beyond pursuing new restrictions being put on prescriptions, there will be a more intentional focus on Big Pharma and those who many believe have made the opioid crisis possible.

Jeff Sessions said the task force will “examine existing state and local government lawsuits against opioid manufacturers to determine if we can be of assistance.”

Meanwhile, Sessions also included the Justice Department is going to be backing a lawsuit in Ohio against major prescription opioid makers.

Ohio VS Opioid Makers Lawsuit

In truth, this lawsuit isn’t just about the state of Ohio. It consolidates more than 400 complaints by cities, counties and Native American tribes nationwide. Buckeye Nation has definitely been hit hard by the opioid crisis, but for now, the stage is set here for a massive effort against questionable practices from opioid makers.

The lawsuit that solicits the Justice Departments attention is pending in Federal District Court in Cleveland. It goes after various companies for using misleading marketing to promote prescription opioids, including:

  • Manufacturers
  • Distributors
  • Dispensers

The lawsuit also accuses the defendants of:

  • Downplaying the risk of addiction to these drugs
  • Failing to report suspicious orders by consumers, which would indicate the drugs were being abused

Furthermore, there are some big names in Big Pharma being listed as defendants, including:

  • Johnson & Johnson
  • Purdue Pharma
  • Teva Pharmaceuticals

The suit is also going after large distributors, such as:

  • McKesson
  • Cardinal Health

Not to mention pharmacy chains like:

  • CVS
  • Walgreens
  • Rite Aid

So how will the Justice Department be engaging in the current lawsuit? How will this new development impact the outcome of the case?

For more important information on the dangers of prescription drugs, download our

FREE E-BOOK “Big Secrets of Big Pharma: Why They Secretly Hope You Get Hooked”

DOWNLOAD FREE E-BOOK

Statement of Interest Against Opioid Makers

During the press briefing, Sessions explained that the Justice Department plans to file what is called a “statement of interest” in the Ohio lawsuit. This is a technique that past administrations typically would only resort to in cases that directly affect the federal government’s interests, such as diplomacy and national security.

However, with the intensity of the opioid crisis being what it is, it is perfectly understandable to make it such a high priority for the current administration to get involved with. So far, recovery advocates have been largely unimpressed with the half-measures that have been presented thus far with the Trump administration to address the issue.

By invoking the statement of interest, the attorney general is legally able to argue on behalf of the government’s interest in any court in the country. However, it does not make the government a plaintiff. All things considered, Sessions said his department will use criminal and civil penalties. He states,

 “We will use whatever tools we have to hold people accountable for breaking our laws.”

Which is quite a statement, considering it isn’t at all common for criminal charges to be brought against Big Pharma.

The Devil Is in the Data

What brought the Justice Department into this began with a discussion on access to certain data. This past Monday, lawyers for the Drug Enforcement Administration (DEA) came to the Ohio courtroom to discuss how much data they would share about the national distribution of painkillers.

The DEA said it would only provide two years of information in the case, asserting that the agency did not want to compromise ongoing criminal investigations. However, Judge Dan Aaron Polster’s request is to provide the sides with nine years of data. He said the agency has until next Monday to decide whether it will comply. This data can assist in determining:

  • The number of pills distributed
  • The locations
  • The distributors

This information could be crucial in allocating liability.

Richard Fields, a lawyer who represents state attorneys general and sovereign Native American nations in opioid litigation, predicts that the statement of interest from the Justice Department “will help unlock this data so that we can hold manufacturers, distributors and pharmacies accountable for flooding communities with pills.”

Therefore, it appears Sessions is going to be taking some big steps toward calling out Big Pharma for their involvement in the opioid crisis. Sessions says the government will be taking a hard look at doctors who overprescribe prescription painkillers. Even legal drugs like these too often lead to addiction and abuse of illegal drugs like heroin.

Ohio Attorney General Mike DeWine says he believes this is a game changer. With all the suffering communities in Ohio have seen over the past several years, we can only hope.

Holding Big Pharma accountable is a huge step. Nevertheless, we should also highlight the need for state and community officials to promote safe and effective addiction treatment. Innovative and holistic recovery programs can make a dramatic difference in helping heal communities. If you or someone you love is struggling, please call toll-free now.

 CALL NOW 1-888-922-5398

Suicide VS Overdose: Study Claims Opioid Deaths Are Misclassified

Suicide VS Overdose: Study Claims Opioid Deaths Are Misclassified

Over the last 15 years, the suicide rate has climbed by an estimated 32%. While the overdose deaths in relation to the opioid crisis have become a constant issue around the country, some researchers suggest that the real suicide rates are even higher, but some of them are being misclassified as overdoses.

So, are more people dying due to drug abuse, or are more people taking their own lives using powerful street drugs and prescription narcotics?

Studying Suicide and Drugs

The idea that many of the deaths recorded as opioid overdoses may have been suicides, according to the researchers, is due to a significant gap between suicide rates and intoxication mortality rates.

A study from the Luskin School of Public Affairs at the University of California, Los Angeles, was published in the journal PLOS One. This study states that both suicide and drug intoxication death rates in the United States have risen over a period of 15 years. Researchers compiled data from the Center for Disease Control and Prevention (CDC) to show:

  • 2000- The suicide rate was 10.40 per 100,000 people
  • 2015- Suicide rate rose to 13.75 deaths per 100,000 people
  • 2000- Drug intoxication mortality rate for those over the age of 15 was 7.81 deaths per 100,000
  • 2015- Drug intoxication death rate for those over the age of 15 rose to 20.07 per 100,000 in 2015

This means that the drug intoxication death rate rose by 257% in those 15 years, while suicide rates only rose by 32%. While 32% is still a devastating number when it comes to such a tragic circumstance, there is still a huge difference between 32% and 257%. These researchers believe this major difference in the reports of mortality rates suggests a lack of suicide reporting.

Difficulties in Death Investigation

One of the big problems, according to the study’s author Mark Kaplan, is resources. Kaplan is a professor of social welfare at UCLA, and he stated to local news sources,

“Unfortunately, part of the problem is due to serious under-resourcing of state and local death investigation systems throughout most of the U.S.

“Many of these deaths were probably suicides, yet reported as accidental self-poisoning rather than intentional self-harm, particularly among the middle-aged.”

The study by Kaplan and his colleagues further explains that when it comes to suicide by overdose, things like an individual’s psychiatric history or the presence of a suicide note are crucial to helping professionals identify a death as a suicide.

“A suicide note, prior suicide attempt or affective disorder was documented in less than one-third of suicides and one-quarter of undetermined deaths,”

“Our incorporation of undetermined deaths, as well as registered suicides, not only provided a window on the nature of suicide misclassification within the undetermined death category but within the accident category—as a much larger reservoir for obscuring drug intoxication suicides.”

So by acknowledging that there is not always an obvious indication that a death is a suicide, even in cases that are classified in suicide, the researchers believe that many deaths that involved drugs have most likely been categorized as overdoses instead of making a deeper inquiry into the circumstances surrounding an individual’s death.

Opioids Causing Ambiguity

With the opioid crisis in America, it has become even more difficult to measure the suicide rates. And that isn’t just this research teams opinion either.

In 2015, the CDC hosted a meeting to address the challenges presented for medical examiners and coroners across the country. The primary focus was concerning cases of fatal intoxication due to opioids and other drugs. The summary of this meeting concluded that drug intoxication deaths may be among the most difficult to determine regarding the manner of death. The summary notes that reasons for such difficulty in having a more accurate manner of death include:

  • Potentially equivocal evidence
  • Intent to die
  • Overlapping demographic groups affected
  • Overlapping premorbid risk factors (e.g., substance abuse, mental health problems).

Opioid addiction, much like any other form of substance use disorder, is often closely connected to other issues, including anxiety, trauma and mental health disorders. Some individuals living with mental health conditions who abuse opioids may be self-medicating and accidentally overdose. But others may be suffering so severely, with conditions like depressive disorders or bipolar disorder, that they ultimately take their own lives intentionally with the powerful drugs. With opioid abuse being so widespread and devastating, the line between the two has begun to blur.

Both studies mentioned clearly indicate in order to truly comprehend an accurate number of suicides by overdose, more research is needed. Both also admit that the number may never be exact.

Even though we will probably never have a definitive answer, the question is still important to ask. By knowing whether opioid deaths are caused by accidents or intentional we can develop better strategies to provide education and prevention.

This is also why mental health should always be a priority when it comes to addiction treatment.

Substance use disorder and suicide are both connected to mental health and personal wellness. Too often they both lead to avoidable tragedies. Therefore, mental health and wellness should be a priority for addiction treatment. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now.

 CALL NOW 1-888-922-5398

Opioids on Wall Street: Addictions Influence on White-Collar World

Opioids on Wall Street: Addictions Influence on White-Collar World

(This content is being used for illustrative purposes only; any person depicted in the content is a model)

The opioid crisis has affected every community in America. Opioids affect rural working class people, those in the inner city and suburbs, or even the wealthy and well-to-do professionals. While drug abuse in business has been highlighted in blockbuster films like the Wolf of Wall Street, the current reality is not far from it. According to addiction experts, substance use disorder is making a sobering impact on the financial industry.

This comes from not just an upscale partying lifestyle, but also from drugs used to manage performance and stress, along with physical pain. According to addiction experts, the financial industry itself is actively turning a blind eye to the issues concerning opioid abuse on Wall Street because money is still the priority, and stigma still gets in the way.

Opioids on Wall Street: White-Collar Confessions

As it stands there is no comprehensive research that takes a detailed look at opioid abuse in Wall Street among finance professionals. So we can’t exactly show the numbers to prove it’s prevalence. However, what we see consistently is a dramatic increase in addiction and overdose rates all over the nation in recent years.

Luckily, professionals from this demographic are beginning to speak out in hopes of progressive change.

One such individual is Trey Laird, a former Wall Street trader, who recently spoke to CNBC about his six-year opioid addiction. During the conversation Laird reiterates the critical understanding that substance use disorder can reach anyone, saying:

“Addiction pervades every single socioeconomic demographic that there is. Every industry, every race, men, women. It doesn’t care who you are,”

After getting clean himself, Laird went on to open a sober living community and says he hopes to specifically serve the Wall Street and white collar demographic.

According to Laird, there has been more talk about opioid addiction among people in higher socioeconomic brackets, but there is still much work that needs to be done. He acknowledges that increasing awareness is doing a great deal, but that the problem is also at an increase. Wall Street may finally be talking about it, but how many professionals will get the help they truly need?

Opioids on Wall Street: Stocks and Stigma

One of the biggest obstacles facing white-collar workers like those in Wall Street is the engrained stigma still attached to addiction. Even with all the shifts in our culture toward a better understanding of substance use and the compassion for those struggling, professionals still have this seemingly unbearable hurdle in front of them.

Truthfully, stigma is something that prevents most people from getting help. Professionals will often be too afraid of losing their jobs to admit they need help. Many in the world of Wall Street and finance may have no information on how to seek out treatment while adhering to their professional boards’ guidelines and business practices.

With white-collar workers, this may be an especially difficult thing because the idea of addiction is so often attached to stereotypes of the unemployable, the homeless, the unreliable and unstable that their high-earning careers might minimize the impact drugs have on their lives. Wall Street stockbrokers and traders might not see themselves as having a problem as long as they can function, which brings in the idea of the “functioning addict.”

Opioids on Wall Street: Function Addiction is Still Addiction

Many white-collar workers who struggle with drugs or alcohol may consider themselves a “functioning addict”, meaning they are less likely see their actions as a problem because they are able to maintain their professional or even personal lives. To make matters worse, frequently the people around someone who is professionally successful will not believe the addiction is real. They may admit that you’ve been careless or destructive in some respects, but will ultimately minimize it due to your financial stability.

As long as you’re making money and paying the bills how could you possibly be “that bad?”

Well, because “functioning addiction” is still an addiction.

Addiction isn’t about whether or not you are able to hold down a steady income. It does not depend on whether or not other people recognize that you have a problem or your competence with your profession. While addiction can and will have an impact on these things, it isn’t always as black and white as most people like to pretend.

Notice how earlier we said you may “maintain” other areas of your life? Well, we mean to say that you can get by for a while, but eventually, the effects of addiction will catch up with you. It could be in the form of serious health consequences or other devastating circumstances. It could take days, months or even years, but it will leave a mark.

Sadly, “functioning addicts” are also far less likely to get the help they desperately need.

Opioids on Wall Street: It Could Be You

While you might be able to keep your addiction secret, in the beginning, things will eventually get worse. Eventually, your addiction will become unmanageable.

If you think you might fit the “functioning addiction” criteria, look at the following questions and answer them honestly.

  • Do you often think about using drugs or drinking?
  • Do you find it hard to stop after you start drinking or using?
  • Are you scheduling your time around drinking or using drugs?
  • Have you tried to stop before, but found that you were unable to?
  • Do you drink or use drugs first thing in the morning?
  • Are you drinking or using drugs at work?
  • Do you hide your drug use or drinking?
  • Have you done something risky, like driven drunk?
  • Do you worry about your drug use or drinking?

If you find you are answering “yes” more than “no” then you should seriously consider speaking with a medical or addiction professional about your drug use or drinking.

The opioid crisis is nothing to be ignored. Despite all that we think we have learned about addiction too many professionals don’t get the help they need. No one is exempt from the destruction of addiction. Opioids don’t care what street you work on, Wall Street or not, they can ruin your life all the same. If you or someone you love is struggling, please call toll-free now. We want to help.

 CALL NOW 1-888-922-5398

Pin It on Pinterest